UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2055-2062

2012

Volltextzugriff (PDF)

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

The Lancet (British edition), 2014-08, Vol.384 (9944), p.665-673

2014

Volltextzugriff (PDF)

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

Journal of clinical oncology, 2009-10, Vol.27 (28), p.4787-4792

2009

Volltextzugriff (PDF)

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2070-2078

2012

Volltextzugriff (PDF)

Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer

Journal of thoracic oncology, 2011-04, Vol.6 (4), p.781-785

2011

Volltextzugriff (PDF)

Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants

Biochimie, 2018-11, Vol.154, p.19-24

2018

Volltextzugriff (PDF)

Lung Carcinomas with EGFR Exon 19 Insertions Are Sensitive to Gefitinib Treatment

Journal of thoracic oncology, 2014-04, Vol.9 (4), p.e31-e33

2014

Volltextzugriff (PDF)

EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts

Oncology research and treatment, 2018-01, Vol.41 (10), p.634-642

2018

Volltextzugriff (PDF)

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer

European journal of cancer (1990), 2020-01, Vol.125, p.49-57

2020

Volltextzugriff (PDF)

Perioperative Nivolumab in Resectable Lung Cancer

The New England journal of medicine, 2024-05, Vol.390 (19), p.1756-1769

2024

Volltextzugriff (PDF)

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

Journal of clinical oncology, 2024-07, Vol.42 (19), p.2317-2326

2024

Volltextzugriff (PDF)

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.243-243

2022

Volltextzugriff (PDF)

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2019-10, Vol.136, p.74-79

2019

Volltextzugriff (PDF)

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2021-07, Vol.35 (4), p.429-444

2021

Volltextzugriff (PDF)

Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial

Clinical lung cancer, 2018-05, Vol.19 (3), p.270-279.e3

2018

Volltextzugriff (PDF)

Prognostic value of non-MHC-restricted killer cell activity in lung cancer

Cancer Immunology Immunotherapy, 1993, Vol.36 (1), p.61-64

1993

Volltextzugriff (PDF)

Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Vol.9 (4), p.e31-e33

2014

Volltextzugriff (PDF)

3062 – THERE IS NO TRANSFER OF MITOCHONDRIA FROM DONOR HEMATOPOIETIC CELLS TO RECIPIENT MSCS AFTER ALLO-HSCT

Experimental hematology, 2024-08, Vol.137, p.104384, Article 104384

2024

Volltextzugriff (PDF)

Human and Technological Progress Towards the Socio-Economic Paradigm of the Future: Part 1

1st edition, 2020

Volltextzugriff (PDF)

Review of the Financial Law Textbook Edited by V.F. Popondopulo and D.A. Petrov — Moscow : Prospect, 2021. — 576 p

Financial Law, 2022-10, Vol.10, p.42-45

2022

Volltextzugriff (PDF)

1-Methyladenine inhibits adenylate cyclase in starfish oocytes

Invertebrate reproduction & development, 1996-12, Vol.30 (1-3), p.153-158

1996

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(23)
Bücher
(1)
Berichte
(1)

Sprache

Englisch
(24)
Russisch
(4)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer

Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants

Lung Carcinomas with EGFR Exon 19 Insertions Are Sensitive to Gefitinib Treatment

EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer

Perioperative Nivolumab in Resectable Lung Cancer

Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Prognostic value of non-MHC-restricted killer cell activity in lung cancer

Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment

3062 – THERE IS NO TRANSFER OF MITOCHONDRIA FROM DONOR HEMATOPOIETIC CELLS TO RECIPIENT MSCS AFTER ALLO-HSCT

Human and Technological Progress Towards the Socio-Economic Paradigm of the Future: Part 1

Review of the Financial Law Textbook Edited by V.F. Popondopulo and D.A. Petrov — Moscow : Prospect, 2021. — 576 p

1-Methyladenine inhibits adenylate cyclase in starfish oocytes

Suchergebnisse filtern